Acute pancreatitis
Conditions
Interventions
DA-1 group:DA 0.5 ug/(kg·min)
DA-2 group:DA 1 ug/(kg·min)
DA-3 group:DA 2 ug/(kg·min)
DA-stable:0.5-2 ug/(kg·min)
DA-lower level:0.5-2 µg/(kg·min)
control group:No intervention
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of acute pancreatitis: according to the 2012 Atlanta classification and definition revision international consensus, the diagnosis of acute pancreatitis needs 2 of the following three characteristics: (1) Abdominal pain is consistent with the characteristics of acute pancreatitis (persistent and severe upper abdominal pain often radiates to the back); (2) The activity of serum lipase (or amylase) was at least 3 times higher than the normal upper limit; (3) Enhanced CT or infrequent magnetic resonance imaging (MRI) or abdominal ultrasonography revealed characteristic changes in acute pancreatitis; 2. Patients admitted within 48 hours after the onset of the disease; 3. Aged 18 to 75 years old; 4. Patients who meet the diagnostic criteria of predicted severe acute pancreatitis (meet the diagnostic criteria of acute pancreatitis, and meet one of the following conditions in the acute phase): (1) PASS > 140; (2) CRP > 150 mg/L; 5. Patients or their family members (guardians) agree to participate in the study, sign informed consent, and agree to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients with hypertension level 2 or hypertension level 1 with poor control under drug treatment; 2. Patients with severe respiratory, cardiovascular, digestive and hematological diseases, as well as psychiatric and infectious diseases; 3. Patients with serious illness who need non medical treatment such as surgery and peritoneal lavage; 4. Patients with advanced tumor; 5. Patients with chronic renal failure caused by organic kidney disease; 6. Patients who were enrolled in other clinical trials 3 months before onset of disease; 7. Patients with pheochromocytoma; 8. Occlusive vascular diseases (or those with previous history), including arterial embolism, atherosclerosis, thromboangiitis obliterans, frostbite (such as frostbite), diabetic endarteritis and Raynaud's disease should be used with caution; 9. Patients with frequent ventricular arrhythmias; 10. Patients with poor circulation; 11. Women during pregnant stage and breast-feed stage.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| heart rate;blood pressure;Dose limiting toxicity and maximum tolerable dose;pass;sap; | — |
Secondary
| Measure | Time frame |
|---|---|
| temperature;Respiratory rate;Main symptoms;laboratory characteristics;Local complications;systemic complications;hospital stay;ICU occupancy rate;SIRS;APACHE II; | — |
Countries
China
Contacts
Public ContactCongying Chen
Shanghai First People's Hospital
Outcome results
None listed